Navigation Links
STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany

ANTONY, France, January 19 /PRNewswire-FirstCall/ -- Stallergenes S.A. today announced that the Paul Ehrlich Institute, the German agency in charge of regulating biological products, has approved its application for a pediatric extension (5-17 years) of the indications for Oralair(R) Grasses, sublingual tablets for desensitization to grass pollens.

The marketing authorization for adults was granted on June 24, 2008. Oralair(R) Grasses will therefore be marketed for both indications in Germany for the 2009 pollen season.

Stallergenes will now begin a mutual recognition procedure for registration of the product in Europe for both the adult and pediatric indications, with Germany as the reference member state. The pivotal phase III pediatric trial, VO 52.06(2), conducted in 278 allergic rhinoconjunctivitis-sufferers aged between 5 and 17 years in 5 European countries (Denmark, France, Germany, Poland, Spain), confirmed the results of the adult trial: an excellent tolerance profile and a statistically and clinically significant reduction in symptoms. The pediatric and adult dosages are identical.

"This new MA(1) for Oralair(R) Grasses represents an important milestone in the field of pediatric desensitization therapy. Thanks to the quality of the clinical trials conducted during the development of the tablet, grass pollen desensitization therapy has now achieved a level of evidence so far unprecedented in children and in line with the requirements of evidence-based-medecine(3). Children are a core target for desensitization therapy, accounting for around 40% of patients."

"Oralair(R) Grasses has already been well received in adults: both its price and its pre- and coseasonal position fit squarely with the expectations of German allergy specialists. This EBM-documented, well-tolerated and easy-to-take treatment, which is effective from the very first season, is set to quickly become firmly established for pediatric use", states Albert Saporta, Chairman and CEO of Stallergenes.

About Oralair(R) Grasses

Oralair(R) Grasses is a tablet for desensitization to grass pollens, the allergen that causes rhinoconjunctivitis and allergic rhinitis in more than 50% of patients in Europe.

With a safe and easy-to-use daily tablet of Oralair(R) Grasses, patients enjoy a very significant alleviation of all their rhinoconjunctivitis symptoms, a marked reduction in their symptomatic medication use and a noticeable improvement in their quality of life.

Oralair(R) Grasses has been shown to be effective in rhinoconjunctivitis caused by allergy to grass pollens from the first season, throughout the entire pollen season and during pollen peaks:

    - in poly- and mono-sensitized patients and asthmatic patients,
    - on every individual symptom, and, in particular, on nasal congestion
      and watery eyes.

Oralair(R) Grasses is indicated as a pre- and coseasonal treatment: treatment should be started four months before the pollen season starts and then be maintained throughout the season. Treatment should be repeated, following the same protocol, for 3 consecutive pollen seasons.

Oralair(R) Grasses contains a mix of five standardized grass pollens, mimicking patients' natural exposure: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum).

The clinical development program has already enrolled around 1,600 patients to date, including 278 children. A pivotal trial aimed at confirming the long-term efficacy of the treatment is currently under way. In line with the program schedule, the results will be communicated at the end of 2009. Finally, the company is presently carrying out a trial in adults, with a view to registration in the USA.

About The Oralair Development Program

According to World Health Organization (WHO) estimates, 20 to 25% of the world's population suffer from respiratory allergic symptoms (rhinitis and/or asthma). By 2020, 50% of the world's population will be affected by allergy according to the ISAAC study. According to WHO, desensitization is the only treatment that addresses the immunological cause of allergy and modifies the natural course of the disease. Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment.

Since 2003, Stallergenes has been running the Oralair program, which addresses these unmet medical needs with EBM-documented, registered allergen tablets that are safe and easy-to-use.

This program consists in the development of tablets for four of the main allergens triggering more than 80% of these allergies: grass pollens, house dust mites, birch pollen and ragweed pollen.

The entire program is in the clinical development stage and is proceeding according to schedule.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had a turnover of 170,9 million euros and provided desensitization treatments to more than 500,000 patients.

Stallergenes is listed on Euronext Paris (Compartment B and is part of the sample composing the SBF 120 index.

    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP
    Additional information is available at:
    (1) Marketing Authorization

(2) Wahn U, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. The Journal of Allergy and Clinical Immunology. January 2009 (Vol. 123, Issue 1, Pages 160-166.e3).

(3) Evidence-Based Medicine (EBM) is defined as "the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients" (Sackett, 1996).

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
2. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
3. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
4. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
7. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
8. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
11. Curemark Appoints Preeminent Pediatrics Gastroenterologist
Post Your Comments:
(Date:10/9/2015)... Lilly and Company (NYSE: LLY ) and Locemia ... Locemia,s intranasal glucagon, a potential treatment for severe hypoglycemia ... which is currently in Phase III clinical trial testing, ... hypoglycemia. --> --> ... formulation that is delivered in an emergency situation using ...
(Date:10/9/2015)... , Oct. 9, 2015 Regardless ... Device environments, corporate communications is perpetually evolving. Due ... and professionals must continuously adjust their business-to-business (B2B) ... these adjustments is difficult, but also critical as ... options. --> ...
(Date:10/9/2015)... -- Regulatory affairs groups within medical device organizations face a ... These specialized groups are charged with ensuring that their ... to the development and marketing of medical device products. While ... their own internal effectiveness and efficiencies to remain productive and ... --> Optimal resourcing and staffing help ...
Breaking Medicine Technology:
... kids are outside playing soccer, baseball, or lacrosse, jumping rope, ... know, there is a trip to the emergency room. Childhood ... is the refined work of physicians and hospitals but it ... while injured. A common problem parents face is how to ...
... Mass., May 15, 2012  IntelligentMDx (IMDx) announced today that ... qualitative in vitro diagnostic test designed for ... (GBS) for use in screening pregnant women and those ... GBS is responsible for life-threatening bacterial infections in newborns, ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... walk with crutches for the rest of my life," said an inventor from San Diego, ... give me more independence and freedom would be amazing. This inspired me to invent a ... STRAP IN to enable an individual to walk with crutches without having to use his ...
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out ... Earnhardt Jr., and all of the stars of the NASCAR Sprint Cup Series. ...
(Date:10/10/2015)... ... 2015 , ... Attending medical school and working on a ... children. Depending on the school, the exact details of the medical program differ; ... in a medical school must complete undergraduate classwork and requirements before moving into ...
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known ... pleased to be recognized by The National Law Journal for inclusion in their ... law firms across the United States who obtained the largest awards for their ...
(Date:10/9/2015)... ... October 09, 2015 , ... Doctors on Liens has ... , to provide highly needed medical care to personal injury victims. When personal ... to diagnose, document and treat the variety of conditions ailing them. With the ...
Breaking Medicine News(10 mins):
... Report: , , Study highlights: , , Cardiac ... EMS personnel due to a number of external factors. , ... to give high-quality CPR and other resuscitation efforts before transporting ... guidelines for transporting cardiac arrest patients and determining when to ...
... Pioneering procedure aims to repair damaged cardiac muscle, surgeons say ... they,ve performed the first procedure in which a patient received ... attack damage. , The 39-year-old man is the first of ... a phase 1 clinical trial being conducted at Cedars-Sinai Heart ...
... obliged to bring unresponsive patient to hospital, study finds , ... heart attack that occurs outside of a hospital are slim, ... hospital anyway because a variety of factors keep them from ... In the United States, paramedics treat almost 300,000 people with ...
... don,t perform better than standard criteria, study finds , ... cardiac risk, such as inflammation-linked C-reactive protein (CRP), ... factors such as smoking, obesity, high cholesterol and physical ... markers have been touted as a better way of ...
... Physiological changes associated with the metabolic syndrome may play ... according to study results published in Cancer Epidemiology, ... Association for Cancer Research. The metabolic syndrome, ... factors including abdominal obesity, high blood glucose levels, impaired ...
... improperly , TUESDAY, June 30 (HealthDay News) -- ... dose for Tylenol and other pain medications should be ... recommended lowering the maximum dose of over-the-counter acetaminophen -- ... , Part of the problem, according to an FDA ...
Cached Medicine News:
ArcticTemp Upright Freezer -20C. Thick wall insulation keeps your samples colder. Reversible door with magnetic gaskets. 2 shelves and a wire basket. Heavy duty compressor with 5 year warranty....
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... a portable system for routine pH, mV ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... automatic buffer recognition for five buffers (pH ...
... The F 265 is a highly accurate portable, ... and temperature measurements. Temperature compensated pH results can ... (ATC) or a 3-in-1 electrode. • This GLP/GMP ... to a printer or a computer. Up to ...
Medicine Products: